Topics

BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda in NSCLC Patients Progressing on Immune Checkpoint Inhibitors

11:34 EST 15 Jan 2020 | FinanzNachrichten

- First stage clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL inhibitor bemcentinib in combination with Keytruda in patients with advanced NSCLC who have fail...

Original Article: BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda in NSCLC Patients Progressing on Immune Checkpoint Inhibitors

NEXT ARTICLE

More From BioPortfolio on "BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda in NSCLC Patients Progressing on Immune Checkpoint Inhibitors"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...